The protein kinases C (PKCs) are a family of serine/threonine kinases involved in regulating multiple essential cellular processes such as survival, proliferation, and differentiation. Of particular interest is the novel, calcium-independent PKC\(\theta\) which plays a central role in immune responses. PKC\(\theta\) shares structural similarities with other PKC family members, mainly consisting of an N-terminal regulatory domain and a C-terminal catalytic domain tethered by a hinge region. This isozyme, however, is unique in that it translocates to the immunological synapse between a T cell and an antigen-presenting cell (APC) upon T cell receptor-peptide MHC recognition. Thereafter, PKC\(\theta\) interacts physically and functionally with downstream effectors to mediate T cell activation and differentiation, subsequently leading to inflammation. PKC\(\theta\)-specific perturbations have been identified in several diseases, most notably autoimmune disorders, and hence the modulation of its activity presents an attractive therapeutic intervention. To that end, many inhibitors of PKCs and PKC\(\theta\) have been developed and tested in preclinical and clinical studies. And although selectivity remains a challenge, results are promising for the future development of effective PKC\(\theta\) inhibitors that would greatly advance the treatment of several T-cell mediated diseases.

1. Introduction

Cells respond to environmental stimuli through complex signal transduction pathways. Among key players are the protein kinase C (PKC) family highlighted by numerous studies in regulation of the cell cycle, cancer development, and the stress response [1]. The particular PKC isozyme activated, its cellular localization, and the ensuing protein–protein interactions differentially affect cell survival [2]. Primarily expressed in lymphoid tissues, hematopoietic cells, and muscle cells [3], the novel isozyme PKC\(\theta\) shares its regulatory N-terminal domain and C-terminal catalytic domain with other PKC family members [1]. PKC\(\theta\), however, plays a unique role in immune responses by modulating multiple molecules such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\(\kappa\)B), activator protein 1 (AP-1), mitogen-activated protein kinase (MAPK), and c-Jun N-terminal kinases (JNK). Interestingly, it is the only member of the PKC family known to translocate to the immunological synapse between a T cell and an antigen-presenting cell (APC) upon T cell receptor-peptide MHC recognition [4, 5]. PKC\(\theta\) interacts physically and functionally with downstream effectors to mediate T cell activation, differentiation, and migration. In addition to its role in inflammation, PKC\(\theta\) is implicated in certain disorders ranging from autoimmunity, neuroinflammatory diseases, muscular dystrophy, cancer, and diabetes. Here we review experimental studies done on PKC\(\theta\) and their contribution to the development of new therapeutic agents, targeting PKC\(\theta\), particularly in inflammatory contexts.
2. The Structural and Functional Features of PKC Family Members

The PKC family consists of 12 serine/threonine kinases that are divided into three groups based on their corresponding activators/cofactors, conventional (cPKCs), novel (nPKCs), and atypical (aPKCs). The cPKCs include the $\alpha$, $\beta$, and $\gamma$ isozymes which are activated by Ca$^{2+}$, diacylglycerol (DAG) and tumor-promoting phorbol esters (PMA), in the presence of phosphatidylinerine (PS) [6, 7]. The nPKCs ($\epsilon$, $\eta$, $\delta$ and $\theta$) are activated by DAG and PMA only. The aPKC group includes $\iota$, $\zeta$, and $\mu$ kinases which are not activated by Ca$^{2+}$, DAG, or PMA but depend on protein-protein interaction for activation such as p62 in the case of PKC $\zeta$ [8–10]. An additional group in the PKC family named PKC-related-kinases (PRKs) was also described [11]. This group is also considered the fourth of the PKC family and consists of three members PRK1–3. Like aPKCs, PRKs do not bind Ca$^{2+}$, DAG, or phorbol esters. They are similar in structure to PKCs except for the C1 domain. In addition, PRKs have HR1 motifs which are not present in other PKCs and are presumably responsible for the RhoA binding property of the PRKs.

The structure of protein kinases consists of a regulatory N-terminal domain and a catalytic C-terminal domain held together by a hinge region [12]. Cleavage of the hinge liberates the catalytic domain leading to constitutive activation of PKC. The catalytic domain includes phosphorylation and autophosphorylation sites (discussed later) and, hence, is referred to as the kinase domain. It also contains two highly conserved regions among all PKC isozymes; the C3 element consists of an ATP-binding site and the C4 region is dedicated for substrate binding [12]. On the other hand, the regulatory moiety contains three domains, the pseudosubstrate domain (autoinhibitory sequence), the C1 domain that binds DAG and phorbol esters, and the C2 domain that binds Ca$^{2+}$ [1]. All protein kinases possess the pseudosubstrate domain, but not all isozymes have functional C1 and C2 cofactor binding domains [13]. For instance, cPKCs contain pseudosubstrate, C1 and C2 domains. The nPKCs have pseudosubstrate, C1 and a variant form of C2 domain making it insensitive to Ca$^{2+}$ activation. The atypical PKCs possess a variant form of C1 with the absence of C2 domain [13].

2.1. Characteristics of Kinase Catalytic Domain and Pseudosubstrate Domain. The structure of the kinase domain was brought to light when the crystal structure of protein kinase A was first resolved by Knighton and colleagues in 1991 [14]. The ATP and protein substrate bind in the kinase cleft situated between two lobes, consisting of $\beta$-sheets at the N-terminus and $\alpha$ helix on the C-terminus [15, 16]. Before it becomes catalytically competent, yet still inactive, nascent PKCs undergo conformational changes. Such changes occur at three phosphorylation sites that are conserved, among PKC isozymes as well as protein kinases A and G [9]. These sites are located at the activation loop (also referred to as T-loop) positioned at the tip of the kinase domain, at the turn-motif named after the “apex of a turn” structure of the PKA, and at the hydrophobic motif in the C-terminal end of the kinase domain. The order by importance of the phosphorylation starts with the foremost and the rate-limiting phosphorylation at the activation loop by phosphoinositide-dependent kinase (PDK-1) [13, 17–19]. PDK-1 requires phosphatidylinositol-3,4,5-triphosphate for PKC $\zeta$ phosphorylation [20–22]. In absence of PDK-1, PKC isozymes become prone to rapid degradation before turning into catalytically competent enzymes [23]. The second step of phosphorylation continues with the phosphorylation of the turn-motif (T638 in PKC$\alpha$ and S643 in PKC$\delta$) followed by phosphorylation of the hydrophobic motif (S657 in PKC$\alpha$ and S662 in PKC$\delta$) [24–26]. In cPKCs, the turn motif and the hydrophobic motif are autophosphorylated, whereas in nPKCs autophosphorylation occurs only on the turn motif; phosphorylation on the hydrophobic motif is carried out by other kinases. Unlike other PKCs, phosphorylation of the activation loop in PKC$\theta$ is sufficient for NF-$\kappa$B stimulation [27]. Studies have shown that mutation at the hydrophobic motif replacing the phosphorylated residue serine by alanine contributes to PKCs thermo-instability [28, 29]. Therefore, the hydrophobic motif, but not the activation loop, is considered a direct mediator for PKC stability [23]. It appears that the hydrophobic motif actually functions as a docking-site for PDK-1 enzyme through its repetitive negatively charged aspartate sequence called PDK-1 interacting fragment (PIF) [16, 30]. This interaction allows PDK-1 to access the activation loop. The atypical PKCs possess an acidic phosphomimetic aspartic acid or glutamic acid in the hydrophobic motif that enhances binding of PDK-1 and phosphorylation of the turn motif rather than the hydrophobic motif in cPKC isozymes and novel PKC$\epsilon$ [31]. How such phosphorylation protects PKCs from degradation is still not fully understood. However, it is well established that the acidic residues surrounding the activation loop and the binding of the pseudosubstrate post-phosphorylation are essential for enzyme stability [32].

The pseudosubstrate domain is located at the extremity of the regulatory site. It was first described by Kemp and colleagues as a stretch of amino acids that resembles the substrate, except that it contains an alanine residue instead of serine/threonine [33]. A pseudosubstrate has a dual function; it controls both maturation and activation prior to cofactor binding [34]. As mentioned earlier, nascent PKCs need to be phosphorylated to become mature or catalytically competent. Binding of the pseudosubstrate shields the catalytic loop from PDK-1 and prevents its phosphorylation as shown in in vitro experiments [35]. Therefore, for PDK-1 to phosphorylate the kinase domain, PKC kinase domain should be in an “open” position devoid of any pseudosubstrate [35]. Once PDK-1 phosphorylates the activation loop, the kinase domain PKC becomes catalytically competent; it undergoes a conformational change indulging the pseudosubstrate to bind at the substrate-binding site. At that point, PKC is said to be “mature” and resistant to phosphatases [35]. For PKC to become catalytically active, upon cofactor binding (DAG,
Ca\(^{2+}\) and PS), another conformational change displaces the pseudosubstrate from the substrate-binding site giving access to the substrate and allowing subsequent phosphorylation [35].

2.2. The Topological Properties of PKCs. The localization of PKC family members in the cell dictates their respective functions. Compartmen talization of PKCs to the membrane is mediated by scaffold/adaptor proteins [34]. Scaffold proteins interact with nascent/competent, mature and active PKC isozymes regulating the kinases’ activities either positively or negatively. Examples of scaffold proteins are: receptor for activated C kinase (RACK), substrates that interacts with C kinase (STICK), receptor for inactive C kinase (RICK), and A-kinase activating protein (AKAP) [34]. RACKs and STICKs bind to active PKCs whereas AKAPs and RICKs interact with inactive PKCs. Binding of RACK increases the phosphorylation capacity of PKCs several-folds independently from the substrate identity [36]. However, STICK itself acts as a substrate for PKC in addition to its function as an anchoring protein [36, 37]. Caveolins represent another group of scaffold that helps PKCs and PKC\(\zeta\) translocate to the caveolar microdomains where they are subsequently activated [38]. AKAP79 recruits PKC isoforms to the post-synaptic dendritic fraction rendering them inactive [39]. Several other scaffold proteins such as CARMA1 (CARD-containing MAGUK protein 1), 14-3-3\(\varepsilon\), and Vav1 are particularly involved in regulating PKC\(\theta\)’s translocation and activation and will be discussed later in the manuscript.

2.3. Termination of the Kinase Activity in PKCs. The kinase activity of PKCs is terminated by dephosphorylation [40]. However, this process takes place when protein kinases are in an “open” conformation, in other words, when the kinase domain is unbound by the pseudosubstrate or when a particular PKC is constitutively active [41]. For cPKCs and nPKCs, dephosphorylation is carried out by the PP2C protein phosphatase at the hydrophobic motif and by interacting with inactive PKCs. Binding of RACK increases the phosphorylation capacity of PKCs several-folds independently from the substrate identity [36]. However, STICK itself acts as a substrate for PKC in addition to its function as an anchoring protein [36, 37]. Caveolins represent another group of scaffold that helps PKCs and PKC\(\zeta\) translocate to the caveolar microdomains where they are subsequently activated [38]. AKAP79 recruits PKC isoforms to the post-synaptic dendritic fraction rendering them inactive [39]. Several other scaffold proteins such as CARMA1 (CARD-containing MAGUK protein 1), 14-3-3\(\varepsilon\), and Vav1 are particularly involved in regulating PKC\(\theta\)’s translocation and activation and will be discussed later in the manuscript.

3. A Novel PKC Isoenzyme, PKC\(\theta\)

3.1. Structural Domains of PKC\(\theta\). Primarily expressed in lymphoid tissues and hematopoietic cells [50], PKC\(\theta\) is a single polypeptide kinase composed of 706 amino acids that typically phosphorylates serine or threonine residues. PKC\(\theta\) shares its structure with other PKC family members; it contains a regulatory N-terminal domain and a C-terminal catalytic domain tethered together by a hinge region as seen in Figure 1 [1]. The regulatory domain of PKC\(\theta\) consists of the C2-like domain sequence, similar to the Ca\(^{2+}\) binding C2 domain of other PKCs, except that it does not really bind Ca\(^{2+}\). The C2-like domain allows PKC\(\theta\) to interact with a receptor for activated C kinase (RACK) which regulates its translocation to the membrane [49]. In addition to the C2-like domain, the regulatory domain of PKC\(\theta\) includes C1a and Cib domains that have diacylglycerol (DAG) and phorbol esters binding sites [51]. The Cib domain has much higher affinity for diacylglycerol than the C1a domain [52]. The pseudosubstrate region in the C1a domain consists of a small sequence of amino acids that mimics a substrate and binds to the substrate-binding cavity in the catalytic domain [33]. However, this sequence lacks phosphorylatable serine and threonine so it prevents access of substrates to the catalytic domain and keeps the enzyme inactive. Moreover, regulatory domains include the variable V1, V2 and V3 domains. The V3 domain, with its proline-rich motif, is unique to PKC\(\theta\), essential and sufficient for its translocation to immunological synapses by linking it to CD28 receptor via the kinase Lck [53, 54].

The crystal structure of PKC\(\theta\) catalytic domain has been published in 2004 [55] revealing an N-terminal lobe and a C-terminal lobe. The catalytic C-terminal domain consists of an ATP binding site, V4, substrate binding site, and V5. ATP binds to a glycine-rich loop (GXGXXG) at the interface of the two lobes while the substrate binds to an \(\alpha\)C helix. Additionally, important elements of the conserved catalytic domain include a kinase activation loop with phosphorylatable threonine 538 (pT538), a hydrophobic motif containing phosphorylatable serine 695 (pS695), and a turn motif containing conserved phosphorylatable serine 676 (pS676) and phosphorylatable serine 685 (pS685) [55]. The catalytic domains of PKCs are highly conserved, with the exception of the variable V5 region consisting of 60–70 amino acids. This variable domain highly contributes to the regulation of PKC\(\alpha\) activity through multiple mechanisms; by stabilizing the kinase through direct interactions with its N-lobe, by interacting with the pseudosubstrate in the N-terminal regulatory domain and by mediating subcellular localization through interaction with RACK [56]. Nothing has been published yet on the role of the V5 domain in PKC\(\theta\) isozyme.

3.2. Physical and Functional Interactions of PKC\(\theta\) with Substrates and Regulators. PKC\(\theta\) can interact either physically or functionally, activating or synergizing with the activity of other proteins. Many examples will be summarized in this section starting with T cells proteins. The 14-3-3 family
proteins were described as potential regulators of PKCs [57]. These proteins associate with several protooncogene and oncogene products modulating their activity. 14-3-3 isoform is highly expressed in T cells and associates with PKCθ in vitro and in intact T cells. 14-3-3 binds directly to PKCθ in the cytosol, preventing its activation and translocation to the membrane [57]. When overexpressed, it can also inhibit the enzymatic activity of PKCθ by blocking its association with substrate and/or ATP. A direct interaction between PKCθ and SAP (SLAM-Associated Protein) was also described in T cell activation signaling [58, 59]. SAP mediates the recruitment and activation of the protein kinase Fyn that, in turn, phosphorylates SLAM (Signaling Lymphocyte Activation Molecule). Phosphorylation of SLAM creates docking sites for many proteins and enzymes such as PKCθ, leading to NF-κB activation [58, 59]. It was also shown that SAP constitutively associates with PKCθ in T cells via arginine 78 of SAP, independently of Fyn, but via the formation of a ternary SLAM/SAP/PKCθ complex following T cell activation [60].

Interestingly, an E3 ubiquitin ligase, Casitas B-lineage lymphoma (Cbl-b) was described to suppress T cell activation when mediated by TCR signaling alone without CD28 costimulatory signals [61]. Upon costimulation with CD28, however, the suppression of T cell activation is removed since Cbl-b gets degraded in a mechanism that depends on the activity of PKCθ [62]. Furthermore in T cell context, the protooncogene Vav, a GDP/GTP exchange factor (GEF), was also described to associate with PKCθ in thymocytes in response to TCR-mediated apoptosis [63]. PKCθ was found to synergize with Vav for the activation of NF-κB [64]. It is likely that Vav helps in the translocation of PKCθ to synaptonemal microdomains leading to their colocalization and T cell activation [65]. It remains to be proved whether Vav translocates to the membrane following PKCθ phosphorylation or by direct contact with PKCθ [66], especially since the interaction between Vav and PKCθ appears to be a functional rather than a physical association [65]. In addition to SAP and Vav, CARMA1 is inducibly phosphorylated on S552 of its linker region by PKCθ upon TCR-CD28 costimulation. This phosphorylation mediates TCR-induced NF-κB activation [67]. Furthermore, it was shown that CARMA1 acts to contribute to the upregulation of the protein mucin in response to the bacterium Haemophilus influenzae and phorbol ester PMA in respiratory epithelial cells via a PKCθ-MEK-ERK pathway [68]. Other interaction mechanisms remain unclear such as the potential interaction between PKCθ and interleukin-2-inducible T-cell kinase (Itk) in T lymphocyte signal transmission [69].

In addition to its roles in regulating the activation and proliferation of lymphocytes, PKCθ appears to have an important role during muscle histogenesis [70]. Recent studies showed that PKCθ is essential for cardiomyocytes survival and cardiac tissue remodeling by preventing cardiomyocytes’ death upon extensive work [71]. In skeletal muscle models, it was not understood why embryonic myoblasts differentiate in the presence of transforming growth factor beta (TGF beta) while fetal myoblasts do not. It was found that PKCθ is selectively expressed in fetal skeletal myoblasts but not in embryonic skeletal myoblasts [70]. Embryonic myoblasts lacking PKCθ did not respond to TGF beta or differentiate in its presence. However, the sensitivity of fetal myoblasts to the inhibition of differentiation exerted by TGF beta is mediated by the expression of PKCθ in these cells [70]. Recently, PKCθ was found to regulate profusion genes caveolin-3 and β1D integrin and induce focal adhesion kinase phosphorylation resulting in mononucleated myoblasts fusion and formation of multinucleated myofibers [72]. In this context, RACK1 acts as an adapter between PKCθ and integrins [73]. Another study shed light on the involvement of PKCθ in endothelial cell migration via integrins [74]. It described a novel 20 kD protein, theta-associated protein or TAP20 whose transcription depends enzymatically on active PKCθ [74]. TAP20 directly interacts with the cytoplasmic tail of the β3 integrin subunit, thus interfering with the integrin-cytoskeleton interaction required for focal adhesion formation [74]. Furthermore, PKCθ was shown to mediate the binding of leukocyte function-associated antigen 1 (LFA-1) on T cells to immunoglobulin-like cell adhesion molecule 1 (ICAM-1) on APCs following T cell activation [75]. In this context, PKCθ associates with RapGEF2 which facilitates Rap1 activation and subsequent surface distribution of LFA-1 [76]. The relocation of LFA-1 and its conformational change increase its binding affinity to ICAM-1 [77]. Moreover, the clusters of LFA-1 on the surface induce actin polymerization and remodeling, thereby enhancing T cell adhesion [78]. Cytoskeletal remodeling also involves the
microtubule cytoskeleton where the microtubule-organizing center (MTOC) becomes oriented towards the APC to enable efficient cargo trafficking toward the APC [79]. Interestingly, it was shown that PKCθ was required for MTOC reorientation [80]. In another context, PKCθ was found to be involved in spectrin-based cytoskeleton remodeling during apoptosis. Spectrin, which is known to link the cell membrane to the actin cytoskeleton, aggregates with PKCθ in the early stages of apoptosis [81]. Notably, a unique role of PKCθ was revealed in intestinal epithelial monolayers where active PKCθ directly phosphorylates tubulin monomers promoting their assembly into microtubules and increasing microtubule stability [82]. Hence, it was shown that loss of PKCθ affects the cytoskeletal integrity leading to an increase in epithelial barrier permeability, a symptom of intestinal inflammation.

3.3. PKCθ in the Immunological Synapses and Lipid Rafts. PKCθ is highly expressed in leukemic Jurkat T cells [83]. It is the only member of PKC family to be recruited to the immunological synapse in effector T cells [4]. Immunological synapses form between a T cell and an antigen-presenting cell (APC) following T cell receptor-peptide MHC recognition [4, 5]. It is composed of a central supramolecular activation cluster (cSMAC) surrounded by a peripheral supramolecular activation cluster (pSMAC). It was found that accumulation of lipid rafts in immunological synapses does not increase upon TCR/CD28 stimulation; they rather reorganize preferentially in the cSMAC instead of pSMAC [84]. PKCθ appears to be recruited to the junction between the cSMAC and pSMAC in a CD28 costimulatory-dependent manner [85, 86], more specifically by physical association with the cytoplasmic tail of CD28 [54]. Many studies investigated the mechanism by which PKCθ translocates to the immunological synapses and revealed that it partially depends on phospholipase C activity and DAG production but also on a novel signaling pathway [85, 87]. It was proposed that such translocation is mediated by the PKCθ regulatory V3 domain and requires Lck [88]. In addition to Lck, all of Vav1, phosphatidylinositol 3-kinase (PI3-K), the small GTPase Rac, and actin cytoskeleton reorganization participate in regulating the membrane localization and consequent activation of PKCθ [87, 89]. In addition to the regulatory domain, the kinase domain is of great importance with respect to the immunological synapse localization of PKCθ. An active kinase domain permits the retention of PKCθ in the immunological synapse, likely via autophosphorylated sites that are still undefined [90].

3.4. Role of PKCθ in Interleukin-2 Production during T Cell Activation. Upon TCR and CD28 costimulation, fully activated PKCθ plays an important role in mediating signaling events that lead to the activation of transcription factors such as NF-κB, AP-1 and NF-AT. The NF-κB signaling pathway is the major target of PKCθ in T cell activation that leads to interleukin-2 (IL-2) production. NF-κB is usually present in the cytosol in an inactive form whereby its nuclear localization sequence is shielded by inhibitors such as IκBαs [91, 92]. These inhibitors, when phosphorylated by PKCθ-activated IKKs, undergo degradation resulting in NF-κB translocation to the nucleus where it regulates gene transcription of IL-2. The activation of IKKs by PKCθ mediated by multiple effectors such as CARMA1 [67], discussed above. Another study revealed a direct interaction between PKCθ and IKKβ that shed light on a different potential pathway linking PKCθ to NF-κB [93]. AP-1, a dimer of Jun and/or Fos proteins is also a transcription factor that regulates IL-2 production. PKCθ activates SEK1, a MAP kinase that phosphorylates and activates JNK, which then activates Jun [94]. A third pathway involving NF-AT is also thought to be essential for full T cell activation, although cross-talk exists between the different PKCθ-dependent IL-2 production pathways [95].

3.5. Regulation of PKCθ Translocation to Lipid Rafts and Activation. PKCθ acts as a kinase receptor for phospholipid esters and DAG to mediate many cellular responses. Hence, PKCθ is regulated by certain lipids, phosphorylation, and ubiquitination. First, lipids modulate PKCθ activity by cofactors such as DAG. The binding of DAG enhances the interaction between PKCθ and the acidic phosphatidylserine [97] which decreases the binding affinity of the pseudosubstrate inhibitor and leads to PKCθ activation as discussed earlier. Second, PKCθ activity is regulated by phosphorylation and autophosphorylation mechanisms in which many kinases participate to allow the translocation of PKCθ to the membrane. Lck directly phosphorylates PKCθ at Y90, which stimulates NF-AT and NF-κB activation in T cells [88, 89]. Lck binding regulates membrane translocation of PKCθ by forming of PKCθ/Lck/CD28 complex [53, 99, 100]. It is still unknown whether or not the Y90 phosphorylation has a direct influence on both the formation of the above complex and PKCθ catalytic activity. Furthermore, it appears that germinal center kinase-like kinase (GLK) phosphorylates PKCθ on T219, a novel S/T residue, and thereafter regulates its translocation to the lipid rafts upon TCR stimulation [101]. Indeed, T219 phosphorylation induces localization of PKCθ to lipid rafts and the immunological synapse, allowing it to activate downstream effectors in TCR signaling, independent from its kinase activity [102].

As for the role of autophosphorylation, T538, S676, S685 and S695 are important regulation sites at the catalytic domain of PKCθ [27, 103]. The PKCθ autophosphorylation sites are interdependent in that when T538 phosphorylation site is lost, the remaining sites S676 an S695 become more
susceptible to dephosphorylation by phosphatases [27]. T538 is a critical site that regulates PKCθ kinase activity and T cell activation [27] but does not seem to influence PKCθ translocation to lipid rafts [102]. Constitutive autophosphorylation of T538 occurs at the activation loop where substrates and cofactors bind near the active site of the kinase domain [104]; this step helps retain the active conformation of PKCθ [55]. Additionally, GLK directly associates with PKCθ in T cells upon anti-CD3 stimulation and phosphorylates the T538 residue [101]. Such phosphorylation at the turn motif contributes to the regulation of the enzyme’s catalytic activity by stabilizing its active conformation [105, 106]. PKCθ’s S676 site is constitutively autoprophosphorylated and its phosphorylation is moderately increased upon anti-CD3/CD28 costimulation [107].

How this phosphorylation affects the activity of PKCθ and downstream NF-κB activation remains controversial. Conversely, autophosphorylation of PKCθ on S685 appears to regulate the function of PKCθ and T cell activation during TCR signaling [103]. S695 is a constitutive autophosphorylation site in the C-terminal hydrophobic motif of PKCθ and is likely induced by CD3 stimulation [89, 107, 108]. Interestingly, PKCθ S695A mutant results in great loss of T538 phosphorylation status [98, 103]. Hence, S695 phosphorylation is required for optimal PKCθ activation and T cell activation during TCR signaling [27, 102, 103] but its role in the regulation of translocation of PKCθ to the membrane is still controversial [89, 108].

As mentioned earlier, PKCs are regulated by degradation following ubiquitination. Upon sustained Ca2+ and calcineurin signaling, a state of energy or antigen unresponsiveness is induced in T cells mediated by proteolytic degradation of PKCs [109]. Indeed, it was shown that PKCθ goes through lysosomal ubiquitination by activation of myriad proteins. Among these proteins is Itch, the endosome-associated E3 ligase, which catalyzes the ubiquitination and ligation of monoubiquitinated PKCθ to Tsg101 receptor, a component of ESCRT-1 complex located on lysosomal vesicles [110].

4. PKCθ Mechanisms of Action in Various Pathologies

Perturbations of PKCθ activity can result in a variety of diseases and disorders including immunological disorders such as autoimmune and inflammatory diseases, cancer, and diabetes. In the following section, we will summarize PKCθ mechanisms of action in various pathologies.

4.1. Autoimmune Responses and Inflammation. PKθ is highly expressed in some immunological disorders and conditions with inflammation. Indeed, PKCθ plays a dual role in inflammation through its differential regulation of effector T cells (Teffs) and regulatory T cells (Tregs) [5, 111]. The renowned translocation and function of PKCθ at the immunological synapse actually occurs in Teffs, either CD4+ or CD8+ T cells, as it promotes their proliferation to mediate inflammation [5]. In Tregs, however, PKCθ is sequestered away from the immunological synapse and this allows TregS to suppress the activity of Teffs in order to maintain balance of immune reactions, provide tolerance to self-antigens, and prevent autoimmunity [111–113]. Hence, increased PKCθ activity has become a hallmark of autoimmune disorders, which result from activation of self-reactive T cells that differentiate into effectors and attack self-tissues [114]. Additionally, overexpression of the PKCθ-activator GLK enhances PKCθ activity and subsequent stimulation of IKK leading to autoimmunity in systemic lupus erythematosus [101]. This is also true in patients with rheumatoid arthritis where GLK expression was significantly higher in their peripheral blood T cells compared to healthy subjects, and it colocalized with phosphorylated PKCθ in T cells [115].

Therapeutically, the inhibition or suppression of PKCθ helps protect cells from autoimmune disorders. For instance, PKCθ-deficient mice show diminished severity, articular cartilage damage, and bone destruction from Th1-dependent antigen-induced arthritis compared to wild-type mice [116]. This could be due to the reduced expression of the cytokines IFN-γ, IL-2, and IL-4 in their CD4+ T cells [116]. Moreover, PKCθ−/− mice immunized with myelin oligodendrocyte glycoprotein are also resistant to development of autoimmune encephalomyelitis, a model for multiple sclerosis. CD4+ T cells from these mice became primed and accumulated in secondary lymphoid organs in the absence of PKCθ, with severely diminished IFN-γ, TNF, and IL-17 production [117–119]. PKCθ is also required for autoimmune hepatitis induced by concanavalin A, which normally activates CD1d-positive NK cells, rapidly resulting in the generation of the cytokines IFN-γ, IL-6, and TNF-α in large amounts that induce liver damage [120, 121]. In another model, immunization of PKCθ-deficient mice with myosin peptide revealed that these animals fail to develop autoimmune myocarditis as well as the IL-17-producing CD4+ cells (Th17) which mediate the disease [122]. In fact, PKCθ promotes differentiation of T helper 17 (Th17) cells through up-regulation of transcription factor Stat3 through NF-κB and AP-1 upon TCR signaling [123].

Moreover, PKCθ is crucial for in vivo development and harmful immune responses of Th2 cells including pulmonary hyperresponsiveness and allergic reactions to inhaled allergens in a model of asthma [124, 125]. However, PKCθ is somewhat dispensable for Th1-mediated responses as it only affects Th1 initial development, but its deficiency does not impair their activation or cytokine production, especially under conditions that involve strong Th1-inducing stimuli [125]. In allogeneic bone marrow transplantation, PKCθ promotes graft-versus-host-disease (GVHD), which is a potentially lethal complication caused by alloreactive donor T cells that recognize mismatched major histocompatibility molecules [126]. However, in the absence of PKCθ, T cell responses triggered in mice by viral infection or administration of an antigen were relatively normal, and the graft-versus-leukemia effect was preserved [126]. PKCθ is also necessary for survival of alloreactive T cells responsible for allograft rejection through up-regulation of the anti-apoptotic protein, Bcl-xl [114, 127]. Taken together, this evidence suggests that inhibition of PKCθ under such conditions may result in more successful transplants due to long-term tolerance of grafts [121, 128].
In addition to its role in regulating autoimmune and immunosuppressive responses, PKCθ is involved in many inflammatory diseases such as nervous and muscular inflammatory diseases. First, PKCθ is involved in inflammatory brain conditions that result in blood-brain barrier dysfunction [129, 130]. The central molecule in such diseases is the proinflammatory interleukin-1β (IL-1β) which induces activation of PKCθ and subsequent phosphorylation of the tight junction protein zona occludens (ZO)-1 thereby reducing transendothelial electrical resistance as is seen in barrier leakage [130]. Second, inflammation is also a major detrimental factor in muscle dystrophy that promotes muscle degeneration thereby obstructing healing. In this context, PKCθ is the suspected player though its pro-inflammatory role [131, 132]. Knockdown of PKCθ in a mouse model of Duchenne muscular dystrophy indeed prevented muscle wasting and enhanced regeneration and performance of muscle tissue [132].

4.2. Cancer. As previously mentioned, PKCθ is essential for T cell proliferation as it induces expression of IL-2 through NF-κB and AP-1. In addition, PKCθ mediates one of the mechanisms by which leukemic T cells are protected from Fas-induced apoptosis by phosphorylating the bcl-2 family protein BAD [83, 133]. PKCθ is also involved in tumor development. For example, it is a downstream player in pre-TCR-Notch3 signaling where its activation of NF-κB is responsible for the development of Notch3-dependent T-cell lymphoma [134].

Moreover, upon pre-TCR activation, PKCθ prevents Notch3 degradation by regulating the phosphorylation and localization of E3 ubiquitin ligase c-Cbl [135]. PKCθ is positively associated with breast cancer cell proliferation and invasion [136, 137]. PKCθ activates Akt, which in turn reduces activity of forkhead box O protein 3a (FOXO3a) and expression of its target genes estrogen receptor α (ERα) and p27 [136]. This pathway results in depression of the transcription factors NF-κB and c-Rel, which are highly implicated in mammary tumorigenesis [136]. In such ER-negative cells, enhanced PKCθ signaling also leads to the activation of ERK1/2 and Ste20-related proline-alanine-rich kinase (SPAK) as well as the phosphorylation of the Fos family protein Fra-1, thereby stabilizing it and regulating its role in the progression and maintenance of invasive breast cancer cell lines [137]. In addition to leukemia and breast cancer, gastrointestinal stromal tumors (GISTs), the most common mesenchymal tumors, are characterized by high expression and activation of PKCθ [138–140]. PKCθ is used as a marker for diagnosis of KIT protein-negative GIST [138, 141]. Knockdown of PKCθ inhibits cyclin A expression but causes the overexpression of the tumor suppressors p21, p27, and p53 resulting in cell-cycle arrest and apoptosis of GIST48 cells [140].

PKCθ plays a central function in the resistance to tumor development through its role in promoting T cell survival [142, 143]. It was found that up-regulation of sarco/endoplasmic reticulum Ca²⁺-ATPase 3 (SERCA3) by tumor environment inhibits PKCθ in human CD4⁺ T and causes retention of NF-κB in the cytosol, leading to apoptosis of these T cells [143]. Studies in PKCθ-deficient mice demonstrated the importance of PKCθ in the immune response to leukemia as these mice had higher incidence and faster onset of the disease than wild-type mice [144]. PKCθ is also expressed in natural killer (NK) cells and is considered critical for NK-cell mediated anti-tumor surveillance [145, 146]. Development of MHC-I-deficient tumor in vivo is more likely in PKCθ−/− mice than in wild-type mice; such phenotype was associated with reduced NK recruitment and activation [145]. In fact, PKCθ phosphorylates WASp-interacting protein (WIP), which is central for the formation of the protein complex required for NK cytotoxic activity [147]. NK cell-activating receptors also require PKCθ for intracellular signaling that leads to generation of IFN-γ [148].

4.3. Diabetes and Insulin Resistance. PKCθ is the mediator between lipid metabolism and insulin resistance, which is a leading cause of type 2 diabetes mellitus [149, 150]. Elevation in plasma free fatty acids levels increases intracellular fatty acyl-CoA and DAG which in turn activates PKCθ in skeletal muscle which phosphorylates S307 on insulin-stimulated insulin receptor substrate 1 (IRS-1) resulting in reduced tyrosine phosphorylation and IRS-1-associated PI3-kinase activity [151–153]. This event leads to insulin resistance by alleviating insulin-stimulated muscle glycogen synthesis. Similar effects of PKCθ were observed in adipose tissue and the liver [154–156]. A more recent study has actually proposed PDK-1 as a direct target of PKCθ in insulin resistance, in a pathway independent from IRS-1/2 [157]. PKCθ negatively regulates insulin receptor activation of PDK-1 by S504/332 phosphorylation, thereby inhibiting PDK-1-mediated Akt phosphorylation and subsequent PI-3K signaling. Up-regulation of PKCθ that is inversely proportional to insulin sensitivity has also been reported in type 2 diabetic subjects [158]. Furthermore, PKCθ expression in critical regions of the amygdala and hypothalamus is linked to diet-induced obesity and reduced insulin signaling at the level of the central nervous system response [159–162].

5. PKCθ as Target in Clinic

Activation of T cells presents the initiating event in immunological disorders and plays an important role in regulating the immune response. Isozyme-specific perturbations in PKC activity have been identified in numerous human diseases [163]. Therefore, the modulation of PKC activity presents an attractive approach for clinical drug development. Accordingly, agents that inhibit PKCs could contribute to the suppression of immune responses to achieve successful transplants and to prevent many immunological disorders resulting from autoimmune and inflammatory diseases. Many hurdles challenge the development of kinase-specific inhibitors including potency, and selectivity. Most of the PKC domains show high sequence and structural similarity among the isoforms, making it difficult to design molecules that selectively target each isoform. Furthermore, the high degree of homology in the kinase region among the more
than 500 kinases in the human genome makes the design of a PKC inhibitor targeting the kinase domain of interest a major challenge [164, 165]. Moreover, PKCs isoforms have revealed many complex interrelationships and interactions. For example, one particular isoform may be involved in different diseases. Several isoforms may be involved in one particular disease, while for a particular disease two PKC isoforms may produce contrary effects. For instance, PKCa and PKCb play opposite roles in the proliferation and apoptosis of glioma cells [166].

5.1. PKC Inhibitors and the Clinical Trials. Inhibitors of PKC can be classified according to their sites of interaction within the PKC protein structure [163]. Inhibitors of the catalytic domain are directed to either the substrate site or ATP-binding site whereas inhibitors of the regulatory domain may target the phospholipid or phorbol ester binding site by mimicking diacylglycerol [167]. Moreover, inhibitors that disrupt protein-protein interactions at a specific subcellular location or with a specific substrate may provide a new approach to selectively inhibit the phosphorylation of substrates between unique regions in each PKC and its corresponding interacting protein or substrate [163]. Although a wealth of inhibitory compounds is available, few demonstrate specificity for either PKC alone or individual PKC isoforms. Many research efforts are underway to develop PKC-based drugs with several compounds currently in clinical trials.

The best characterized ATP-competitive small molecules are the bisindolylmaleimides [168]. These water-soluble compounds bind to the ATP-binding pocket and limit phosphorylation. The classic example, staurosporine, has pan-PKC activity, binding to all isozymes as well as several other serine/threonine kinases [169]. The experimental and docking interactions of staurosporine with PKCδ displayed important hydrogen bonding with different amino acid residues of the PKCδ active site [163]. In fact, staurosporine is one of the most powerful PKC inhibitors in in vitro models [163]. However, its poor kinase selectivity hampered its further development, prompting efforts to synthesize more PKC-selective analogues. Among these are 7-hydroxystaurosporine or UCN-01 [170] and N-benzoyl-staurosporine [171], which have less PKC-inhibitory activity than the parent compound, but a higher degree of PKC selectivity when assayed for inhibition of different kinases [172]. However, these agents display specificity against conventional isoforms of PKC over novel Ca²⁺ independent isoforms. Sotrastaurin (AE8071) is a PKC inhibitor that has strong and specific activity against PKCb, PKCε, and PKCδ and lesser effect on PKCδ, PKCε, and PKCθ, suggesting that sotrastaurin would inhibit not only T cells, but also a variety of other cells. It inhibits more than 200 other kinases, including those important for early T cell activation, such as Lck. Sotrastaurin acts through PKC to inhibit T-cell activation that is initiated by the binding of peptide-MHC complexes and CD28 costimulation [173, 174]. In vivo data from rodents and nonhuman primates confirmed the potential of sotrastaurin in preventing allograft rejection and reducing the inflammatory response [175, 176]. Results from an initial clinical trial in patients with psoriasis showed improvements in clinical and histological assessments [177]; however, data from early trials in kidney transplant recipients were less encouraging. Sotrastaurin is currently used as an immunosuppressant in phase I trials for liver transplantation [178], and phase II trials for renal transplantation [179]. Although sotrastaurin appears to be well-tolerated based on published clinical trial data, long-term data is needed to confirm the safety and efficacy profile of this novel compound. Efforts to develop a more selective inhibitor led to the discovery of enzastaurin [180–183] and ruboxistaurin [184], which are more selective for PKCβ over other isoforms. Furthermore, Midostaurin (also known as PKC412 or n-benzoylstaurosporine) exhibits improved selectivity for PKC-ATP binding sites, but shows modest isozyme specificity [185, 186]. These inhibitors are undergoing clinical trials. As for enzastaurin, phase I studies showed prolonged disease stabilization in patients with lung cancer, colorectal carcinoma and renal carcinoma [187]. Ongoing clinical trials of enzastaurin alone or in combination with conventional chemotherapies are being investigated in recurrent brain tumor (Phase I), advanced or metastatic malignancies (Phase II), prostate cancer (Phase II), breast cancer, ovarian cancer, and peritoneal cavity cancer [188]. Concerning Ruboxistaurin, it has shown efficacy in the treatment of diabetic retinal and renal abnormalities both in preclinical and human studies [189]. Midostaurin was well-tolerated in phase I study in patients with malignant melanoma but unfortunately phase II trial failed to demonstrate significant clinical activity [185].

The best characterized compound targeting the activator binding C1 domain is bryostatin-1 [190]. Bryostatin-1 is a partial agonist of several members of the PKC family [191]. The binding of bryostatin-1 to PKC results in PKC activation, autophosphorylation, and translocation to the cell membrane [190]. Bryostatin-1-bound PKC is then downregulated by ubiquitination and degradation in proteasomes [190]. Bryostatin-1 is expected to modulate classical PKC isoforms associated with Ca²⁺ signaling as well as novel isoforms independent of Ca²⁺ [190]. Bryostatin-1 has been investigated for anticancer activity in phase I and II clinical trials using a wide range of tumor types [192, 193] and showed promising activity in the treatment of refractory acute leukemia and indolent hematologic malignancies [194–196]. However, several phase II studies were disappointing in melanoma [197], colorectal cancer [198], and gastric carcinoma [199]. Moreover, bryostatin-1 has demonstrated significant chemosensitizing activity when combined with conventional therapeutics including arabinofuranosylcytosine [200], tamoxifen [201], fludarabine [202], taxol [203] in leukemia cells. Protection of PKC from being downregulated by the strong ligand, phorbol ester, led to the design of selective PKC-binding bryostatin analogues. These molecules show selectivity in binding to the C1 domain of various PKC isoforms and may represent a novel class of PKC regulators [204].

5.2. PKCβ Inhibitors in Preclinical Studies. A large number of PKCβ inhibitors have been reported. These can be classified
on the basis of their parent scaffolds, such as aminopyrimidine, pyridine carbonitrile (phenyl, furan, benzofuran, benzothiophene and vinyl phenyl analogs) and thieno (2,3-b) pyridine-5-carbonitriles (2-alkenyl and 2-phenyl) derivatives (2-phenyl and 4-amino indole modification) (for chemical structures, refer to review [194]). Compounds belonging to the amino pyrimidine class are the first discovered inhibitors of PKCθ and are considered more selective than members of any other category [205].

Different derivatives have been developed by making appropriate modifications in groups R1, R2 and R3 [206]. For instance, R1 may be substituted by NO2 and CF3 groups; R2 may be substituted by cyclohexane ring whereas R3 by some bulkier groups like 2-bromo benzylamine, 2-chloro benzylamine. The group substitution of amino pyrimidine derivatives can affect its inhibitory activity. For example, the replacement of some groups such as nitro (–NO2) with CF3 group decreases the activity of molecules by ten times; whereas the presence of the nitro (–NO2) group at the 5th position and substitution of hydrogen atom of amino group at the 2nd position with 2-bromobenzylamine, 2-SCH2 benzylamine and 2-SCF3 benzylamine group increases the potency of molecules in comparison with other substitution groups [207]. Moreover, the stereoisomerism and the geometric isomerism (cis, trans) can affect the biological activity of inhibitors. The pyridine carbonitrile category of PKCθ inhibitors consists of C-5 substituted 3-carbonitrile pyridine derivatives. In the derivative inhibitors, C-4 and C-5 positions are substituted with amino indole and different kinds of heteroaryl/aryl groups, respectively [207, 208]. On the basis of substituents at C-5 position, different derivatives have been developed like phenyl, furan, benzofuran, benzothiophene and phenyl vinyl analogues of pyridine carbonitrile. A series of 5-phenyl-3-pyridinecarbonitriles [209], 5-vinyl-3-pyridinecarbonitriles [210], 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles [211], 5-vinylaryl-3-pyridinecarbonitriles [212] were synthesized.

Preclinical studies have assessed the best analogs among each series by assaying their IC50 values for the inhibition of PKCθ along with their metabolic stability in rat liver microsomes and their ability to block the production of interleukin-2 in stimulated human whole blood [213]. These compounds showed improved microsomal half-lives as well as decrease of interleukin-2 production. Molecules belonging to the category of thieno[2,3b]pyridine-5-carbonitriles are highly selective in nature. They are classified into two categories on the basis of substitution at their 2nd position, that is, 2- alkenyl, phenyl and 2-aryl derivatives [213]. A series of 2-alkenyl thieno[2,3b]pyridine-5-carbonitriles [214] and 4-((indol-5-ylamino)thieno[2,3-b]pyridine-5-carbonitriles were synthesized [215]. These compounds showed a decrease in interleukin-2 production by anti-CD3 and anti-CD28 activated T-cells derived from wild-type mice, with a reduced effect on activated T-cells from PKCθ knockout mice.

The experience with PKCθ inhibitors highlights several challenges for the future. PKCθ is an attractive therapeutic target, but clinically available inhibitors need to be more specific and selective against different PKC isoforms.

6. Conclusion

PKCθ is involved in many signaling pathways that control immune responses and other cellular activities, in normal physiology as well as certain disease states. Particularly, evidence highlights the T-cell activating role of PKCθ as an initiating event in many immunological disorders. Hence, the modulation of PKC activity becomes a challenge that, once overcome, will be useful in medical applications such as the regulation of autoimmune diseases and graft rejection. Accordingly, inhibitors of PKCs and PKCθ have been developed and tested in preclinical and clinical studies. Results are promising for the future development of more specific and selective inhibitors that can greatly enhance the treatment of several T-cell mediated diseases like asthma, arthritis, multiple sclerosis, autoimmunity, and organ transplantation.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Ghassan Dbaibo, Rouba Hage-Sleiman, and Asmaa B. Hamze designed the review; Rouba Hage-Sleiman, Asmaa B. Hamze, Lina Reslan, and Hadile Kobeissy wrote the paper and revised it; Ghassan Dbaibo edited and approved the final version of the paper.

References

[1] A. C. Newton, “Protein kinase C: structure, function, and regulation,” Journal of Biological Chemistry, vol. 270, no. 48, pp. 28495–28498, 1995.

[2] A. Bononi, C. Agnoletto, E. De Marchi et al., “Protein kinases and phosphatases in the control of cell fate,” Enzyme Research, vol. 2011, Article ID 329098, 26 pages, 2011.

[3] J. D. Chang, Y. Xu, M. K. Raychowdhury, and J. A. Ware, “Molecular cloning and expression of a cDNA encoding a novel isoform of protein kinase C (nPKC): a new member of the nPKC family expressed in skeletal muscle, megakaryoblastic cells, and platelets,” The Journal of Biological Chemistry, vol. 268, no. 19, pp. 14208–14214, 1993.

[4] C. R. F. Monks, H. Kupfer, I. Tamir, A. Barlow, and A. Kupfer, “Selective modulation of protein kinase C-θ during T-cell activation,” Nature, vol. 385, no. 6611, pp. 83–86, 1997.

[5] A. Zanin-Zhorov, M. L. Dustin, and B. R. Blazar, “PKCθ function at the immunological synapse: prospects for therapeutic targeting,” Trends in Immunology, vol. 32, no. 8, pp. 358–363, 2011.

[6] M. Inoue, A. Kishimoto, Y. Takai, and Y. Nishizuka, “Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain,” Journal of Biological Chemistry, vol. 252, no. 21, pp. 7610–7616, 1977.

[7] Y. Takai, A. Kishimoto, U. Kikkawa, T. Mori, and Y. Nishizuka, “Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein
kinase system,” *Biochemical and Biophysical Research Communications*, vol. 91, no. 4, pp. 1218–1224, 1979.

[8] G. Y. Kim, P. Nigro, K. Fujiwara, J. Abe, and B. C. Berk, “p62 binding to protein kinase Cζ regulates tumor necrosis factor α-induced apoptotic pathway in endothelial cells,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 32, no. 12, pp. 2974–2980, 2012.

[9] A. C. Newton, “Protein kinase C: poised to signal,” *The American Journal of Physiology—Endocrinology and Metabolism*, vol. 298, no. 3, pp. E395–E402, 1999.

[10] Y. Pu, M. L. Peach, S. H. Garfield, S. Wincovitch, V. E. Marquez, and P. M. Blumberg, “Effects on ligand interaction and membrane translocation of the positively charged arginine residues situated along the C1 domain binding cleft in the atypical protein kinase C isoforms,” *The Journal of Biological Chemistry*, vol. 281, no. 44, pp. 33773–33788, 2006.

[11] H. Mellor and P. J. Parker, “The extended protein kinase C superfamily,” *Biochemical Journal*, vol. 332, part 2, pp. 281–292, 1998.

[12] Y. Nishizuka, “Protein kinase C and lipid signaling for sustained cellular responses,” *The FASEB Journal*, vol. 9, no. 7, pp. 484–496, 1995.

[13] A. C. Newton, “Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions,” *Chemical Reviews*, vol. 101, no. 8, pp. 2353–2364, 2001.

[14] D. R. Knighton, J. H. Zheng, L. F. ten Eyck et al., “Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase,” *Science*, vol. 253, no. 5018, pp. 407–414, 1991.

[15] S. S. Taylor and E. Radzio-Andzelm, “Three protein kinase structures define a common motif,” *Structure*, vol. 2, no. 5, pp. 345–355, 1994.

[16] A. C. Newton, “Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm,” *Biochemical Journal*, vol. 370, part 2, pp. 361–371, 2003.

[17] A. Toker and A. C. Newton, “Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site,” *Journal of Biological Chemistry*, vol. 275, no. 12, pp. 8271–8274, 2000.

[18] E. M. Dutil, A. Toker, and A. C. Newton, “Regulation of conventional protein kinase C isozymes by phosphoinositide-dependent kinase 1 (PDK-1),” *Current Biology*, vol. 8, no. 25, pp. 1366–1375, 1998.

[19] J. A. Le Good, W. H. Ziegler, D. B. Parekh, D. R. Alessi, P. Cohen, and P. J. Parker, “Protein kinase C isoforms controlled by phosphoinositide 3-kinase through the protein kinase PDK1,” *Science*, vol. 281, no. 5385, pp. 2042–2045, 1998.

[20] M. M. Chou, W. Hou, J. Johnson et al., “Regulation of protein kinase Cζ by PI 3-kinase and PDK-1,” *Current Biology*, vol. 8, no. 19, pp. 1069–1077, 1998.

[21] E. D. Sonnenburg, T. Gao, and A. C. Newton, “The phosphoinositide-dependent kinase, PDK-1, phosphorylates conventional protein kinase C isoforms by a mechanism that is independent of phosphoinositide 3-kinase,” *Journal of Biological Chemistry*, vol. 276, no. 48, pp. 45289–45297, 2001.

[22] P. Storz and A. Toker, “3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling,” *Frontiers in Bioscience*, vol. 7, pp. d886–d902, 2002.

[23] A. Balendran, G. R. Hare, A. Kieloch, M. R. Williams, and D. R. Alessi, “Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms,” *The FEBS Letters*, vol. 484, no. 3, pp. 217–223, 2000.

[24] A. Behn-Krappa and A. C. Newton, “The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation,” *Current Biology*, vol. 9, no. 14, pp. 728–737, 1999.

[25] D. Parekh, W. Ziegler, K. Yonezawa, K. Hara, and P. J. Parker, “Mammalian TOR controls one of two kinase pathways acting upon nPKCδ and nPKCε,” *Journal of Biological Chemistry*, vol. 274, no. 49, pp. 34758–34764, 1999.

[26] W. H. Ziegler, D. B. Parekh, J. A. Le Good et al., “Rapamycin-sensitive phosphorylation of PKC on a carboxy-terminal site by an atypical PKC complex,” *Current Biology*, vol. 9, no. 10, pp. 522–529, 1999.

[27] Y. Liu, C. Graham, A. Li, R. J. Fisher, and S. Shaw, “Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear-factor-κB induction,” *Biochemical Journal*, vol. 361, no. 2, pp. 255–265, 2002.

[28] F. Bornancin and P. J. Parker, “Phosphorylation of protein kinase C-α on serine 657 controls the accumulation of active enzyme and contributes to its phosphatase-resistant state,” *The Journal of Biological Chemistry*, vol. 272, no. 6, pp. 3544–3549, 1997.

[29] A. S. Edwards and A. C. Newton, “Phosphorylation at conserved carboxyl-terminal hydrophobic motif regulates the catalytic and regulatory domains of protein kinase C,” *Journal of Biological Chemistry*, vol. 272, no. 29, pp. 18382–18390, 1997.

[30] T. Gao, A. Toker, and A. C. Newton, “The carboxy terminus of protein kinase c provides a switch to regulate its interaction with the phosphoinositide-dependent kinase, PDK-1,” *The Journal of Biological Chemistry*, vol. 276, no. 22, pp. 19588–19596, 2001.

[31] T. Ikenoue, K. Inoki, Q. Yang, X. Zhou, and K. L. Guan, “Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling,” *The EMBO Journal*, vol. 27, no. 14, pp. 1919–1931, 2008.

[32] J. W. Orr and A. C. Newton, “Requirement for negative charge on ’activation loop’ of protein kinase C,” *The Journal of Biological Chemistry*, vol. 269, no. 44, pp. 27715–27718, 1994.

[33] C. House and B. E. Kemp, “Protein kinase C contains a pseudosubstrate prototope in its regulatory domain,” *Science*, vol. 238, no. 4834, pp. 1726–1728, 1987.

[34] D. Ron and M. G. Kazanietz, “New insights into the regulation of protein kinase C and novel phorbol ester receptors,” *The FASEB Journal*, vol. 13, no. 13, pp. 1658–1676, 1999.

[35] E. M. Dutil and A. C. Newton, “Dual role of pseudosubstrate in the coordinated regulation of protein kinase C by phosphorylation and diacylglycerol,” *The Journal of Biological Chemistry*, vol. 275, no. 14, pp. 10697–10701, 2000.

[36] D. Ron, C.-H. Chen, J. Caldwell, L. Jamieson, E. Orr, and D. Mochly-Rosen, “Cloning of an intracellular receptor for protein kinase c: a homolog of the β subunit of G proteins,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 3, pp. 839–843, 1994.

[37] D. Mochly-Rosen and A. S. Gordon, “Anchoring proteins for protein kinase C: a means for isozyme selectivity,” *The FASEB Journal*, vol. 12, no. 1, pp. 35–42, 1998.

[38] N. Oka, M. Yamamoto, C. Schwencke et al., “Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation
of kinase activity by the caveolin scaffolding domain peptide,” *Journal of Biological Chemistry*, vol. 272, no. 52, pp. 33416–33421, 1997.

[39] T. M. Klauck, M. C. Faux, K. Labudda, L. K. Langeberg, S. Jaken, and J. D. Scott, “Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein,” *Science*, vol. 271, no. 5255, pp. 1589–1592, 1996.

[40] T. Gao, J. Brognard, and A. C. Newton, “The phosphatase PHLPP controls the cellular levels of protein kinase C,” *Journal of Biological Chemistry*, vol. 283, no. 10, pp. 6300–6311, 2008.

[41] E. M. Dutil, L. M. Keranen, A. A. DePaoli-Roach, and A. C. Newton, “In vivo regulation of protein kinase C by trans phosphorylation followed by autophosphorylation,” *The Journal of Biological Chemistry*, vol. 269, no. 47, pp. 29359–29362, 1994.

[42] J. Brognard and A. C. Newton, “PHLPPing the switch on Akt and protein kinase C signaling,” *Trends in Endocrinology & Metabolism*, vol. 19, no. 6, pp. 223–230, 2008.

[43] J. H. Ahn, T. M. Cannons, J. Z. Wu, J. Gomez-Rodriguez et al., “Biochemical and genetic evidence for a SAP-PKC-theta interaction contributing to IL-4 regulation,” *The Journal of Immunology*, vol. 185, no. 5, pp. 2819–2827, 2010.

[44] D. J. Burns and R. M. Bell, “Protein kinase C contains two \( \theta \) isoforms,” *Molecular and Cellular Biology*, vol. 12, no. 11, pp. 1314–1336, 2002.

[45] G. Baier, D. Telford, L. Giampa et al., “Molecular cloning and characterization of PKCtheta, a novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells,” *The Journal of Biological Chemistry*, vol. 268, no. 7, pp. 4997–5004, 1993.

[46] D. J. Burns and R. M. Bell, “Protein kinase C contains two phorbol ester binding domains,” *The Journal of Biological Chemistry*, vol. 266, no. 27, pp. 18330–18338, 1991.

[47] H. R. Melowic, R. V. Stahelin, N. R. Blatner et al., “Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase C theta,” *Journal of Biological Chemistry*, vol. 282, no. 29, pp. 21467–21476, 2007.

[48] K.-F. Kong, T. Yokosuka, A. J. Canonigo-Balancio, N. Isakov, T. Saito, and A. Altman, “A motif in the V3 domain of the kinase PKC-theta determines its localization in the immunological synapse and functions in T cells via association with CD28,” *Nature Immunology*, vol. 12, no. 11, pp. 1105–1112, 2011.
F. Zappelli, D. Willems, S.-I. Osada et al., “The inhibition of differentiation caused by TGFβ in fetal myoblasts is dependent upon selective expression of PKCβ: a possible molecular basis for myoblast diversification during limb histogenesis,” Developmental Biology, vol. 180, no. 1, pp. 156–164, 1996.

R. Paoletti, A. Maifei, L. Madaro et al., “Protein kinase C theta is required for cardiomyocyte survival and cardiac remodeling,” Cell Death and Disease, vol. 1, no. 5, article e45, 2010.

L. Madaro, V. Marrocco, P. Fiore et al., “PKCβ signaling is required for myoblast fusion by regulating the expression of caveolin-3 and β1δ integrin upstream focal adhesion kinase,” Molecular Biology of the Cell, vol. 22, no. 8, pp. 1409–1419, 2011.

J. Liliental and D. D. Chang, “Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit,” The Journal of Biological Chemistry, vol. 273, no. 4, pp. 2379–2383, 1998.

S. Tang, Y. Gao, and J. A. Ware, “Enhancement of endothelial cell migration and in vitro tube formation by TAP20, a novel beta 5 integrin-modulating, PKC theta-dependent protein,” The Journal of Cell Biology, vol. 147, no. 5, pp. 1073–1084, 1999.

I. Michalczuk, A. F. Sikorski, L. Kotula, R. P. Junghans, and J. Liliental, “Protein kinase C theta is an early hallmark of flu-rap1,” Cell, vol. 112, no. 12, pp. 4617–4627, 2003.

J. C. Porter, M. Bracke, A. Smith, D. Davies, and N. Hogg, “Signaling through integrin LFA-1 leads to filamentous actin polymerization and remodeling, resulting in enhanced T cell adhesion,” Journal of Immunology, vol. 168, no. 12, pp. 6330–6335, 2002.

M. Huse, “Microtubule-organizing center polarity and the immunological synapse: protein kinase C and beyond,” Frontiers in Immunology, vol. 3, p. 235, 2012.

E. J. Quann, X. Liu, G. Altan-Bonnet, and M. Huse, “A cascade of protein kinase C isoforms promotes cytoskeletal polarization in T cells,” Nature Immunology, vol. 12, no. 7, pp. 647–654, 2011.

P. M. Dubielecka, M. Grzybek, A. Kolondra et al., “Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells,” Molecular and Cellular Biochemistry, vol. 339, no. 1-2, pp. 63–77, 2010.

A. Banan, L. J. Zhang, M. Shaikh, J. Z. Fields, A. Farhadi, and A. Keshavarzian, “β1δ-isofrom of PKC is required for alterations in cytoskeletal dynamics and barrier permeability in intestinal epithelium: a novel function for PKC-β1δ,” American Journal of Physiology—Cell Physiology, vol. 287, no. 1, pp. C218–C234, 2004.

M. Villalba and A. Altman, “Protein kinase C-θ (PKCθ), a potential drug target for therapeutic intervention with human T cell leukemias,” Current Cancer Drug Targets, vol. 2, no. 2, pp. 125–134, 2002.

W. R. Burack, K. H. Lee, A. D. Holdorf, M. L. Dustin, and A. S. Shaw, “Cutting edge: quantitative imaging of raft accumulation in the immunological synapse,” The Journal of Immunology, vol. 169, no. 6, pp. 2837–2841, 2002.

J. Huang, P. F. Lo, T. Zal et al., “CD28 plays a critical role in the segregation of PKC theta within the immunologic synapse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 14, pp. 9369–9373, 2002.

T. Yokosuka, W. Kobayashi, K. Sakata-Sogawa et al., “Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation,” Immunity, vol. 29, no. 4, pp. 589–601, 2008.

A. Altman and M. Villalba, “Protein kinase C-θ (PKCθ): it’s all about location, location, location,” Immunological Reviews, vol. 192, no. 1, pp. 53–63, 2003.

K. Bi, Y. Tanaka, N. Coudronnieri et al., “Antigen-induced translocation of PKC-theta to membrane rafts is required for T cell activation,” Nature Immunology, vol. 2, no. 6, pp. 556–563, 2001.

M. Villalba, K. Bi, J. Hu et al., “Translocation of PKCθ in T cells is mediated by a nonconventional, PI3-K- and Vav-dependent pathway, but does not absolutely require phospholipase C,” Journal of Cell Biology, vol. 157, no. 2, pp. 253–263, 2002.

N. G. Cartwright, A. K. Kashyap, and B. C. Schaefer, “An active kinase domain is required for retention of PKCtheta at the T cell immunological synapse,” Molecular Biology of the Cell, vol. 22, no. 18, pp. 3491–3497, 2011.

N. Coudronnieri, M. Villalba, N. Englund, and A. Altman, “NF-xB activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-θ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 7, pp. 3394–3399, 2000.

X. Lin, A. O’Mahony, Y. Mu, R. Gelezunis, and W. C. Greene, “Protein kinase C-θ participates in NF-xB activation induced by CD3-CD28 costimulation through selective activation of IκB kinase β,” Molecular and Cellular Biology, vol. 20, no. 8, pp. 2933–2940, 2000.

A. Khoshnan, D. Bae, C. A. Tindell, and A. E. Nel, “The physical association of protein kinase Cθ with a lipid raft-associated inhibitor of xB factor kinase (IKK) complex plays a role in the activation of the NF-xB cascade by TCR and CD28,” Journal of Immunology, vol. 165, no. 12, pp. 6933–6940, 2000.

A. Avraham, S. Jung, Y. Samuels, R. Seger, and Y. Ben-Neriah, “Co-stimulation-dependent activation of a JNK-kinase in T lymphocytes,” European Journal of Immunology, vol. 28, no. 8, pp. 2320–2330, 1998.

P. M. Dubielecka, K. Kofler, T. Gruber et al., “Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells,” Journal of Experimental Medicine, vol. 197, no. 11, pp. 1525–1535, 2003.

A. Altman, S. Kaminski, V. Busuttil et al., “Positive feedback regulation of PLCγ1Ca2+ signaling by PKCθ in reconstituted T cells via a Tec kinase-dependent pathway,” European Journal of Immunology, vol. 34, no. 7, pp. 2001–2011, 2004.

J. W. Orr and A. C. Newton, “Interaction of protein kinase C with phosphatidyserine. 2. Specificity and regulation,” Biochemistry, vol. 31, no. 19, pp. 4667–4673, 1992.

Y. Liu, S. Witte, Y.-C. Liu, M. Doyle, C. Elly, and A. Altman, “Regulation of protein kinase Cθ function during T cell activation by Lck-mediated tyrosine phosphorylation,” Journal of Biological Chemistry, vol. 275, no. 5, pp. 3603–3609, 2000.

R. Tavano, G. Gri, B. Molon et al., “CD28 and lipid rafts coordinate recruitment of Lck to the immunological synapse of human T lymphocytes,” The Journal of Immunology, vol. 173, no. 9, pp. 5392–5397, 2004.
[100] E. Hofinger, H. Sticht, R. Tavano, and A. Viola, “Multiple modes of interaction between Lck and CD28,” Journal of Immunology, vol. 174, no. 7, pp. 3839–3840, 2005.

[101] H.-C. Chuang, J.-L. Lan, D.-Y. Chen et al., “The kinase GLK controls autoimmunity and NF-kB signaling by activating the kinase PKC-θ in T cells,” Nature Immunology, vol. 12, no. 11, pp. 1113–1118, 2011.

[102] N. Thuille, I. Heit, F. Fresser et al., “Characterization of protein kinase C theta activation loop autophosphorylation and the kinase domain catalytic mechanism,” Biochemistry, vol. 44, no. 28, pp. 9563–9573, 2005.

[103] B. Nolen, S. Taylor, and G. Ghosh, “Regulation of protein kinases; controlling activity through activation segment conformation,” Regulation of protein kinases, vol. 15, pp. 661–675, 2004.

[104] A. Messerschmidt, S. Macieira, M. Velarde et al., “Crystal structure of the catalytic domain of human atypical protein kinase C iota reveals interaction mode of phosphorylation site in turn motif,” Journal of Molecular Biology, vol. 352, no. 4, pp. 918–931, 2005.

[105] N. Grodsy, Y. Li, D. Bouzida et al., “Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor,” Biochemistry, vol. 45, no. 47, pp. 13970–13981, 2006.

[106] K. Lee, P. Gudapatii, S. Dragovic et al., “Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways,” Immunity, vol. 32, no. 6, pp. 743–753, 2010.

[107] M. Freeley, Y. Volkov, D. Kelleher, and A. Long, “Stimulus-induced phosphorylation of PKC theta at the C-terminal hydrophobic-motif in human T lymphocytes,” Biochemical and Biophysical Research Communications, vol. 334, no. 2, pp. 619–630, 2005.

[108] V. Heissmeyer, F. Macián, S.-H. Im et al., “Calcineurin imposes T cell unresponsiveness through targeted proteinolysis of signaling proteins,” Nature Immunology, vol. 5, no. 3, pp. 255–265, 2004.

[109] S. Vardhana, K. Choudhuri, R. Varma, and M. L. Dustin, “Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster,” Immunity, vol. 32, no. 4, pp. 531–540, 2010.

[110] E. Y. Zhang, K. F. Hong, and A. Altman, “The yin and yang of protein kinase C-theta (PKCθeta): a novel drug target for selective immunosuppression,” Advances in Pharmacology, vol. 66, pp. 267–312, 2013.

[111] S. Sakaguchi, T. Yamaguchi, T. Nomura, and M. Ono, “Regulatory T cells and immune tolerance,” Cell, vol. 133, no. 5, pp. 775–787, 2008.

[112] A. Zanin-Zhorov, Y. Ding, S. Kumari et al., “Protein kinase C-theta mediates negative feedback on regulatory T cell function,” Science, vol. 328, no. 5976, pp. 372–376, 2010.

[113] M.-J. Kwon, R. Wang, J. Ma, and Z. Sun, “PKC-theta is a drug target for prevention of T cell-mediated autoimmunity and allograft rejection,” Endocrine, Metabolic & Immune Disorders Drug Targets, vol. 10, no. 4, pp. 367–372, 2010.

[114] Y.-M. Chen, H.-C. Chuang, W.-C. Lin et al., “Germinal center kinase-like kinases overexpression in T cells as a novel biomarker in rheumatoid arthritis,” Arthritis & Rheumatism, vol. 65, no. 10, pp. 2573–2582, 2013.

[115] A. M. Healy, E. Izmailova, M. Fitzgerald et al., “PKC-theta-deficient mice are protected from thl-dependent antigen-induced arthritis,” Journal of Immunology, vol. 177, no. 3, pp. 1886–1893, 2006.

[116] S.-L. Tan, J. Zhao, C. Bi et al., “Resistance to experimental autoimmune encephalomyelitis and impaired IL-17 production in protein kinase Cβ-deficient mice,” The Journal of Immunology, vol. 175, no. 11, pp. 7635–7641, 2005.

[117] K. Anderson, M. Fitzgerald, M. DuPont et al., “Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases,” Autoimmunity, vol. 39, no. 6, pp. 469–478, 2006.

[118] X. Fang, R. Wang, J. Ma, Y. Ding, W. Shang, and Z. Sun, “Ameliorated ConA-induced hepatitis in the absence of PKCθeta,” PLoS ONE, vol. 7, no. 2, Article ID e31174, 2012.

[119] Z. Sun, “Intervention of PKC-θ as an immunosuppressive regimen,” Frontiers in Immunology, vol. 3, p. 225, 2012.

[120] B. J. Marsland, C. Nembrini, K. Grün et al., “TLR ligands act directly upon T cells to restore proliferation in the absence of protein kinase C-theta signaling and promote autoimmune myocarditis,” Journal of Immunology, vol. 178, no. 6, pp. 3466–3473, 2007.

[121] M. J. Kwon, J. Ma, Y. Ding, R. Wang, and Z. Sun, “Protein kinase C-theta promotes Th17 differentiation via upregulation of Stat3,” The Journal of Immunology, vol. 188, no. 12, pp. 5887–5897, 2012.

[122] B. J. Marsland, T. J. Soos, G. Spáth, D. R. Littman, and M. Kopf, “Protein kinase Cβ is critical for the development of in vivo T helper (Th)2 cell but not Th-1 cell responses,” The Journal of Experimental Medicine, vol. 200, no. 2, pp. 181–189, 2004.

[123] S. Salek-Ardakani, T. So, B. S. Halteman, A. Altman, and M. Croft, “Differential regulation of Th2 and Th1 lung inflammatory responses by protein kinase Cβ,” Journal of Immunology, vol. 173, no. 10, pp. 6440–6447, 2004.

[124] J. O. Valenzuela, C. Iclozan, M. S. Hossain et al., “PKCβ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice,” The Journal of Clinical Investigation, vol. 119, no. 12, pp. 3774–3786, 2009.

[125] S. Manicasamy, D. Yin, Z. Zhang, L. L. Molinero, M. L. Alegre, and Z. Sun, “A Critical role for protein kinase C-theta-mediated T cell survival in cardiac allograft rejection,” Journal of Immunology, vol. 181, no. 1, pp. 513–520, 2008.

[126] C. C. Bronk, X.-Z. Yu, and A. A. Beg, “Targeting PKCβ in alloreactivity and graft-versus-host-disease: unanswered questions and therapeutic potential,” Frontiers in Immunology, vol. 3, p. 259, 2012.

[127] C. L. Willis, D. S. Meske, and T. P. Davis, “Protein kinase C activation modulates reversible increase in cortical blood-brain barrier permeability and tight junction protein expression during hypoxia and posthypoxic reoxygenation,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 11, pp. 1847–1859, 2010.

[128] R. R. Rigor, R. S. Beard Jr, O. P. Litovka, and S. Y. Yuan, “Interleukin-β-induced barrier dysfunction is signaled through PKC-θ in human brain microvascular endothelium,” The American Journal of Physiology—Cell Physiology, vol. 302, no. 10, pp. C1513–C1522, 2012.

[129] D. V. N. Kumar, J. Shanmugasundaram, C. Sundaram, and M. P. J. S. Anandaraj, “Activity of novel protein kinase C and
[161] H. Oh, S. Boghossian, D. A. York, and M. Park-York, “The effect of high fat diet and saturated fatty acids on insulin signaling in the amygdala and hypothalamus of rats,” Brain Research, vol. 1537, pp. 191–200, 2013.

[162] M. Park-York, S. Boghossian, H. Oh, and D. A. York, “PKCθ expression in the amygdala regulates insulin signaling, food intake and body weight,” Obesity, vol. 21, no. 4, pp. 755–764, 2013.

[163] D. Mochly-Rosen, K. Das, and K. V. Grimes, “Protein kinase C, an elusive therapeutic target?” Nature Reviews Drug Discovery, vol. 11, no. 12, pp. 937–957, 2012.

[164] G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, “The protein kinase complement of the human genome,” Science, vol. 298, no. 5600, pp. 1912–1934, 2002.

[165] P. M. Blumberg, N. Kedei, N. E. Lewin et al., “Wealth of opportunity—the CI domain as a target for drug development,” Current Drug Targets, vol. 9, no. 8, pp. 641–652, 2008.

[166] R. Mandil, E. Ashkenazi, M. Blass et al., “Protein kinase Cα and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells,” Cancer Research, vol. 61, no. 11, pp. 4612–4619, 2001.

[167] P. Geraldis and G. L. King, “Activation of protein kinase C and its impact on diabetic complications,” Circulation Research, vol. 106, no. 8, pp. 1319–1331, 2010.

[168] S. E. Wilkinson, P. J. Parker, and J. S. Nixon, “Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C,” Biochemical Journal, vol. 294, no. 2, pp. 335–337, 1993.

[169] M. W. Karaman, S. Herrgard, D. K. Treiber et al., “A quantitative analysis of kinase inhibitor selectivity,” Nature Biotechnology, vol. 26, no. 1, pp. 127–132, 2008.

[170] C. M. Seynaeve, M. G. Kazanietz, P. M. Blumberg, E. A. Sausville, and P. J. Worland, “Differential inhibition of protein kinase C isoforms by UCN-01, a staurosporine analogue,” Molecular Pharmacology, vol. 45, no. 6, pp. 1207–1214, 1994.

[171] C. Monnerat, R. Henrikkson, T. le Chevalier et al., “Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer,” Annals of Oncology, vol. 15, no. 2, pp. 316–323, 2004.

[172] J. Budworth and A. Gescher, “Differential inhibition of cytosolic and membrane-derived protein kinase C activity by staurosporine and other kinase inhibitors,” FEBS Letters, vol. 362, no. 2, pp. 139–142, 1995.

[173] J.-P. Evenou, J. Wagner, G. Zenke et al., “The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation,” The Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 792–801, 2009.

[174] J. Wagner, P. von Matt, R. Sedrani et al., “Discovery of 3-(IH-indol-3-yl)-4-[2-(4-hydroxyphenyl)quinazolin-4-yl]-pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isoforms,” Journal of Medicinal Chemistry, vol. 52, no. 20, pp. 6193–6196, 2009.

[175] G. Weckbecker, C. Pally, C. Beerli et al., “Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720,” Transplant International, vol. 23, no. 5, pp. 543–552, 2010.

[176] Y. H. Fang, D. J. Joo, B. J. Lim et al., “AEB-071 versus tacrolimus monotherapy to prevent acute cardiac allograft rejection in the rat: a preliminary report,” Transplantation Proceedings, vol. 42, no. 3, pp. 976–979, 2010.

[177] S. Manicassamy, “Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis,” Current Opinion in Investigational Drugs, vol. 10, no. 11, pp. 1225–1235, 2009.

[178] J. M. Kovarik, P. Neuhaus, U. Cillo et al., “Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients,” Transplant International, vol. 24, no. 3, pp. 276–283, 2011.

[179] M. Matz, M. Naik, M.-F. Mashreghi, P. Glander, H.-H. Neumayer, and K. Budde, “Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation,” Expert Opinion on Drug Metabolism & Toxicology, vol. 7, no. 1, pp. 103–113, 2011.

[180] K. W. Lee, G. K. Sang, H. P. Kim et al., “Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells,” Cancer Research, vol. 68, no. 6, pp. 1916–1926, 2008.

[181] M. J. Robertson, B. S. Kahl, J. M. Vose et al., “Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1741–1746, 2007.

[182] T. N. Kreisl, S. Kotliaova, J. A. Butman et al., “A phase II/II trial of enzastaurin in patients with recurrent high-grade gliomas,” Neuro-Oncology, vol. 12, no. 2, pp. 181–189, 2010.

[183] B. Glimelius, M. Lahn, S. Gawande et al., “A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer,” Annals of Oncology, vol. 21, no. 5, pp. 1020–1026, 2010.

[184] L. P. Aiello, L. Vignati, M. J. Sheetz et al., “Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the protein kinase c β inhibitor-diabetic retinopathy study and the protein kinase c β inhibitor-diabetic retinopathy study 2,” Retina, vol. 31, no. 10, pp. 2084–2094, 2011.

[185] M. J. Millward, C. House, D. Bowtell et al., “The multi kinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study,” British Journal of Cancer, vol. 95, no. 7, pp. 829–834, 2006.

[186] T. Fischer, R. M. Stone, D. J. DeAngelo et al., “Phase IIIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3,” Journal of Clinical Oncology, vol. 28, no. 28, pp. 4339–4345, 2010.

[187] M. A. Carducci, L. Musib, M. S. Kies et al., “Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4092–4099, 2006.

[188] E. Galanis and J. C. Buckner, “Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1097–1098, 2010.

[189] R. P. Danis and M. J. Sheetz, “Ruboxistaurin: PKC-beta inhibition for complications of diabetes,” Expert Opinion on Pharmacotherapy, vol. 10, no. 17, pp. 2913–2925, 2009.

[190] M. K. Sun and D. L. Alkon, “Bryostatin-I: pharmacology and therapeutic potential as a CNS drug,” CNS Drug Reviews, vol. 12, no. 1, pp. 1–8, 2006.

[191] B.-F. Ruan and H.-L. Zhu, “The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development,” Current Medicinal Chemistry, vol. 19, no. 16, pp. 2652–2664, 2012.
